Emerging anticoagulant drugsBATES, Shannon M; WEITZ, Jeffrey I.Arteriosclerosis, thrombosis, and vascular biology. 2003, Vol 23, Num 9, pp 1491-1500, issn 1079-5642, 10 p.Article

The ecarin clotting time, a universal method to quantify direct thrombin inhibitorsNOWAK, Götz.Pathophysiology of haemostasis and thrombosis (Print). 2003, Vol 33, Num 4, pp 173-183, issn 1424-8832, 11 p.Article

Food-drug interactionsCHENG, Tsung O.International journal of cardiology. 2006, Vol 106, Num 3, pp 392-393, issn 0167-5273, 2 p.Article

Development of argatroban as an anticoagulant and antithrombin agent in JapanIKOMA, Hidenobu.Pathophysiology of haemostasis and thrombosis (Print). 2002, Vol 32, pp 23-28, issn 1424-8832, 6 p., SUP3Conference Paper

Evaluation of Dabigatran Exposures Reported to Poison Control CentersCONWAY, Susan E; SCHAEFFER, Scott E; HARRISON, Donald L et al.The Annals of pharmacotherapy. 2014, Vol 48, Num 3, pp 354-360, issn 1060-0280, 7 p.Article

Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activityVAN RYN, Joanne; STANGIER, Joachim; HAERTTER, Sebastian et al.Thrombosis and haemostasis. 2010, Vol 103, Num 6, pp 1116-1127, issn 0340-6245, 12 p.Article

The management of patients with heparin-induced thrombocytopenia who require anticoagulant therapyHASSELL, Kathryn.Chest. 2005, Vol 127, Num 2, pp 1S-8S, issn 0012-3692, SUPArticle

Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young menJOHANSSON, Susanne; WAHLANDER, Karin; LARSON, Göran et al.Blood coagulation & fibrinolysis. 2003, Vol 14, Num 7, pp 677-684, issn 0957-5235, 8 p.Article

A clinical-laboratory algorithm incorporating optical density value to predict heparin-induced thrombocytopeniaRUF, Kathryn M; BENSADOUN, Eric S; DAVIS, George A et al.Thrombosis and haemostasis. 2011, Vol 105, Num 3, pp 553-559, issn 0340-6245, 7 p.Article

Recognition, treatment, and prevention of heparin-induced thrombocytopenia : Review and updateGREINACHER, Andreas; WARKENTIN, Theodore E.Thrombosis research. 2006, Vol 118, Num 2, pp 165-176, issn 0049-3848, 12 p.Article

Original Article: Pharmacist-Managed Direct Thrombin Inhibitor Protocol Improves Care of Patients with Heparin-Induced ThrombocytopeniaLOBO, Bob; FINCH, Christopher K; HOWARD-THOMPSON, Amanda et al.Hospital pharmacy (Philadelphia, PA). 2010, Vol 45, Num 9, pp 705-711, issn 0018-5787, 7 p.Article

Drug Monitoring of Argatroban Using the Ecarin Chromogenic AssayNOWAK, Götz; LANGE, Ute; BUCHA, Elke et al.Seminars in thrombosis and hemostasis. 2008, Vol 34, pp 81-86, issn 0094-6176, 6 p., SUP1Article

Thrombin-activated thrombelastography for evaluation of thrombin interaction with thrombin inhibitorsTAKETOMI, Taro; SZLAM, Fania; VINTEN-JOHANSEN, Jakob et al.Blood coagulation & fibrinolysis. 2007, Vol 18, Num 8, pp 761-767, issn 0957-5235, 7 p.Article

Inhibition of thrombin-induced feedback activation of factor V: a potential pathway for inhibition of thrombin generation by melagatranBOSTRÖM, Stig L; DAGNELID, Emelie; HANSSON, Göran F. H et al.Blood coagulation & fibrinolysis. 2004, Vol 15, Num 1, pp 25-30, issn 0957-5235, 6 p.Article

Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatranSTANGIER, Joachim; FEURING, Martin.Blood coagulation & fibrinolysis. 2012, Vol 23, Num 2, pp 138-143, issn 0957-5235, 6 p.Article

Cases of heparin-induced thrombocytopenia elucidate the syndromeRICE, Lawrence.Chest. 2005, Vol 127, Num 2, pp 21S-26S, issn 0012-3692, SUPArticle

Methods for the monitoring of direct thrombin inhibitorsHAFNER, Gerd; ROSER, Markus; NAUCK, Matthias et al.Seminars in thrombosis and hemostasis. 2002, Vol 28, Num 5, pp 425-430, issn 0094-6176, 6 p.Article

Transition to an oral anticoagulant in patients with heparin-induced thrombocytopeniaBARTHOLOMEW, John R.Chest. 2005, Vol 127, Num 2, pp 27S-34S, issn 0012-3692, SUPArticle

Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?DICKNEITE, Gerhard; HOFFMAN, Maureane.Thrombosis and haemostasis. 2014, Vol 111, Num 2, pp 189-198, issn 0340-6245, 10 p.Article

Measuring Direct Thrombin Inhibitors With Routine and Dedicated Coagulation Assays: Which Assay Is Helpful?CURVERS, Joyce; DE KERKHOF, Daan Van; STROOBANTS, An K et al.American journal of clinical pathology. 2012, Vol 138, Num 4, pp 551-558, issn 0002-9173, 8 p.Article

Bivalirudin : Current use of biologicals in thrombosis and haemostasisWARKENTIN, Theodore E; GREINACHER, Andreas; KOSTER, Andreas et al.Thrombosis and haemostasis. 2008, Vol 99, Num 5, pp 830-839, issn 0340-6245, 10 p.Article

Overview of Direct Thrombin Inhibitors in Clinical PracticeBOUNAMEAUX, Henri.Seminars in thrombosis and hemostasis. 2008, Vol 34, pp 12-17, issn 0094-6176, 6 p., SUP1Article

Percutaneous interventions in patients with immune-mediated heparin-induced thrombocytopeniaNIKOLSKY, Eugenia; DANGAS, George D.Seminars in thrombosis and hemostasis. 2004, Vol 30, Num 3, pp 305-314, issn 0094-6176, 10 p.Article

The mechanism of action of rivaroxaban ― an oral, direct Factor Xa inhibitor ― compared with other anticoagulantsMICHEL SAMAMA, Meyer.Thrombosis research. 2011, Vol 127, Num 6, pp 497-504, issn 0049-3848, 8 p.Article

Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formationYOUNG, Guy; YONEKAWA, Karyn E; NAKAGAWA, Peggy A et al.Blood coagulation & fibrinolysis. 2007, Vol 18, Num 2, pp 97-103, issn 0957-5235, 7 p.Article